Messaging Intervention to Increase Medicare Annual Wellness Visits -- The NUDGE AWV Clinical Trial
June 5, 2026 updated by: Laura Feemster
Messaging Intervention to Increase Medicare Annual Wellness Visits: The MIMA Randomized Clinical Trial
Medicare Annual Wellness Visits (AWVs) are critical for addressing preventive care needs among older adults, yet the most recent estimates from the Center for Medicare Services suggest less than 50% of eligible patients take advantage of this free healthcare benefit.
Behavioral science-informed messaging interventions offer a promising strategy to increase AWV participation by guiding patient behavior.
In this study, investigators will evaluate a health system initiative that utilizes personalized email and text messages to encourage Medicare beneficiaries to schedule and attend their AWVs.
This approach aims to boost patient engagement in preventive health services, ultimately improving care outcomes for older adult populations
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The Centers for Medicare & Medicaid Services (CMS) recommends Annual Wellness Visits (AWVs) to encourage preventive care and improve long-term health outcomes for Medicare beneficiaries. These visits are designed to provide a proactive approach to healthcare by focusing on identifying risk factors, updating medical histories, and developing personalized prevention plans that promote early detection of diseases. By prioritizing prevention over treatment, AWVs help reduce the overall cost burden on the healthcare system while enhancing patient engagement and empowering individuals to take a more active role in managing their health. Yet despite these benefits, most Medicare members who are eligible for an AWV - at no cost to them - do not complete one.
Behavioral science research suggests that personalized messages, designed to facilitate action, can have significant impacts on health behavior. Studies have found these messaging interventions can increase vaccination rates, cancer screening rates, and other care gap closure.
Study Type
Interventional
Enrollment (Actual)
29842
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63134
- Ascension Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 65 or older
- Have either a mobile phone number or an email address on file with the health system
- Included in and non-compliant on the Ascension AWV Clinical Priority Goal measure
- Have consented to receive electronic communications from the health system
Exclusion Criteria:
- Patients whose primary care providers are exempted from the campaign by the health system
- Completed MAWV appointment in previous 30 days
- Has an upcoming AWV appointment scheduled
- Have received a nudge campaign from the Clinical Transformation team in the past 90 days
- Patients who have previously opted out of receiving electronic communications from the health system in our message delivery platform (Salesforce)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
This is a group will serve as usual care and have no intervention during the study period
|
|
|
Experimental: Two Messages
This group will receive two messages as part of the study -- one email and one text message.
|
This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
|
|
Experimental: Up To Five Messages
This group will receive up to five messages as part o the study -- two emails and three text messages.
|
This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Annual Wellness Visit scheduling
Time Frame: 14 days
|
Percentage of patients who schedule an AWV
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completed Annual Wellness Visit
Time Frame: 90 Days
|
Percentage of patients who have completed an AWV
|
90 Days
|
|
Days to Annual Wellness Visit Completion
Time Frame: 90 days
|
Number of days to AWV appointment completion
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breast cancer screening
Time Frame: 180 days
|
Completion of breast cancer screening post intervention
|
180 days
|
|
Colon Cancer Screening
Time Frame: 180 days
|
Completion colon cancer screening post intervention
|
180 days
|
|
Ordering of tests for breast cancer screening
Time Frame: 90 days
|
Ordering of tests for breast cancer screening
|
90 days
|
|
Ordering of tests for colon cancer screening
Time Frame: 90 days
|
Ordering of tests for colon cancer screening
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2024
Primary Completion (Actual)
November 12, 2024
Study Completion (Actual)
April 27, 2025
Study Registration Dates
First Submitted
October 10, 2024
First Submitted That Met QC Criteria
October 10, 2024
First Posted (Actual)
October 15, 2024
Study Record Updates
Last Update Posted (Actual)
June 8, 2026
Last Update Submitted That Met QC Criteria
June 5, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAS20240013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Has patient information that we are not approved to share
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.